Edgewise Therapeutics (EWTX) Enterprise Value (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Enterprise Value data on file, last reported at -$33.2 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 33.47% year-over-year to -$33.2 million; the trailing twelve-month figure through Mar 2026 stood at -$33.2 million (up 33.47% YoY), and the FY2025 full-year result was -$61.1 million, down 46.76% from the prior year.
• Enterprise Value grew to -$33.2 million in Q1 2026, from -$61.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$22.0 million in Q4 2022 to a low of -$563.3 million in Q3 2025.
• A 5-year average of -$145.6 million and a median of -$48.2 million in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value slumped 1394.37% in 2024 and jumped 90.63% in 2025, its largest moves.
• Tracing EWTX's Enterprise Value over 5 years: stood at -$22.0 million in 2022, then sank by 291.47% to -$86.1 million in 2023, then soared by 51.61% to -$41.7 million in 2024, then slumped by 46.76% to -$61.1 million in 2025, then soared by 45.69% to -$33.2 million in 2026.
• Business Quant data shows EWTX's Enterprise Value at -$33.2 million in Q1 2026, -$61.1 million in Q4 2025, and -$563.3 million in Q3 2025.